Scalp Care Regulatory Classification: Cosmetic vs Quasi-Drug Status by Market Guide

Overview #

Regulatory classification is not a paperwork problem. It is a product strategy decision that determines your formula, your claims, your packaging, your timeline, and your cost structure — before you brief a single ingredient. Scalp care sits in one of the most fragmented regulatory zones in personal care: the same active at the same concentration can be a cosmetic in Germany, a quasi-drug in Japan, and a drug-adjacent product requiring pre-market approval in South Korea. We see brand partners get this wrong constantly, usually because they locked in a claims direction before checking which regulatory bucket their target market puts it in. By the time they come to us, the formula is already briefed and the packaging is in design. That is the worst possible moment to find out.

Why Classification Varies So Dramatically by Market #

The core tension is this: scalp care products often target conditions — dandruff, hair loss, seborrheic dermatitis — that regulators in some markets treat as medical territory. The EU draws the line at mechanism of action and intended purpose under EU Cosmetics Regulation 1223/2009. If your product claims to treat or prevent a disease, it exits cosmetic territory entirely. The FDA operates similarly under FDA Cosmetics Guidelines, but with the added complexity of OTC drug monographs that create a defined pathway for certain actives — zinc pyrithione at 0.3–2%, selenium sulfide at 1%, coal tar at 0.5–5% — to function as cosmetics with drug-level claims, provided they follow monograph rules exactly.

Japan and South Korea are different animals. Japan’s quasi-drug (医薬部外品) system under the Pharmaceutical and Medical Device Act creates a middle category that does not exist in Western frameworks. Approved actives at approved concentrations — minoxidil at 1% for women and up to 5% for men in certain formats, or ingredients like glycyrrhizinic acid and hinokitiol on the positive list — can carry efficacy claims that would be drug claims in the EU. South Korea’s NMPA Cosmetic Regulation equivalent, the Ministry of Food and Drug Safety (MFDS), runs a functional cosmetics system with a similar logic: pre-approved ingredient-concentration combinations can make specific efficacy claims without full drug registration.

China sits in its own category. The NMPA functional cosmetics framework, updated significantly in 2021, requires separate registration for products making claims around hair loss prevention (防脱发). This is not a notification process. It is a full dossier submission with efficacy substantiation data, and the review timeline runs 6–12 months in practice. We have had brand partners underestimate this by a factor of three on timeline.

The table above is a simplification. Every cell has exceptions. But it gives you the decision framework we use at the start of every scalp brief.

The OTC Monograph Route in the US — What It Actually Means for Formulation #

Most brand partners who come to us wanting an “anti-dandruff” positioning for the US market assume the OTC monograph route is straightforward. It is not complicated, but it is rigid. The FDA’s OTC Drug Monograph for dandruff, seborrheic dermatitis, and psoriasis specifies not just the active and concentration, but the dosage form, the labeling language, and in some cases the vehicle restrictions. Zinc pyrithione must appear in the Drug Facts panel. The product must carry an NDC number. Manufacturing must comply with 21 CFR Part 211 cGMP — which is pharmaceutical GMP, not cosmetic GMP.

On our production line, this means a separate quality system for OTC batches. Different batch record format, different in-process testing, different release criteria. The cost delta is real: OTC-compliant manufacturing typically adds 15–25% to unit production cost compared to a cosmetic equivalent, before you factor in the regulatory filing overhead on the brand side.

Here is where brands consistently get surprised. The monograph actives — zinc pyrithione, selenium sulfide, coal tar, salicylic acid, sulfur — are effective. The clinical evidence base for zinc pyrithione specifically is solid. One double-blind, vehicle-controlled RCT (n=246, 12 weeks) demonstrated a 73% reduction in adherent scalp flaking versus 28% for vehicle control, measured by trained grader assessment using a 0–10 scale. That is the kind of data that justifies the regulatory overhead. What the monograph does not give you is differentiation. Every competitor using zinc pyrithione at 1% is making the same claims with the same active. The brand story has to come from the cosmetic co-actives, the sensory profile, the delivery system — none of which can appear in the Drug Facts panel.

We almost always push back when a brand wants to lead with the OTC active in their marketing. The monograph claim is the floor, not the ceiling. Build the brand story around what the cosmetic portion of the formula does.

Japan Quasi-Drug: The Positive List Is Shorter Than You Think #

The quasi-drug pathway sounds attractive until you actually read the positive list. For hair and scalp products (育毛剤 category), the approved actives are well-defined: minoxidil, adenosine, t-flavanone, glycyrrhizinic acid derivatives, hinokitiol, panthenyl ethyl ether, and a handful of others. Concentrations are fixed. You cannot use a novel active and claim quasi-drug status — the active must be on the list, at the listed concentration, in an approved format.

What this means practically: if your hero ingredient is something like a proprietary peptide complex or a novel botanical extract, it cannot anchor a quasi-drug claim in Japan. You have two options. Register it as a cosmetic with softer claims, or run a full drug approval process that takes years and costs more than most indie brands can absorb. We have seen brands spend 18 months developing a formula around an ingredient that was never going to qualify for quasi-drug status in Japan. That is a painful conversation to have late in development.

The sensory and formulation constraints are also real. Quasi-drug products in Japan are subject to manufacturing standards under the Pharmaceutical and Medical Device Act, and the consumer expectation for quasi-drug scalp tonics is a specific aesthetic — lightweight, often alcohol-based, with a clinical feel. Trying to make a quasi-drug scalp serum that feels like a luxury cosmetic is harder than it sounds. The regulatory format and the consumer format are not always aligned.

For brands targeting Japan specifically, our recommendation is to design two SKUs from the start: a quasi-drug tonic for the efficacy claim, and a cosmetic scalp treatment for the sensory and brand experience. It adds complexity, but it is cleaner than trying to make one product do both jobs.

China NMPA Special Cosmetics: The Efficacy Substantiation Requirement #

This is where most international brands hit a wall. China’s 2021 cosmetics regulation overhaul created a mandatory efficacy substantiation requirement for special cosmetics, including hair loss prevention products. The dossier must include human efficacy testing data — not just safety data, not just in vitro data. Human subjects, conducted or verified by a NMPA-recognized testing institution, with results that support the specific claims on pack.

The NMPA Cosmetic Regulation framework specifies that hair loss prevention claims require a combination of consumer perception studies and instrumental or clinical measurement. In practice, the testing institutions we work with require a minimum 60-subject panel, 12-week duration, with phototrichogram or TrichoScan measurement at baseline, week 6, and week 12. The primary endpoint is typically hair density (hairs/cm²) or anagen/telogen ratio. Secondary endpoints usually include consumer self-assessment questionnaires and investigator global assessment.

We ran one of these studies for a brand partner in 2023. Baseline phototrichogram showed 187 hairs/cm² in the test area. At week 12, the treatment group showed 201 hairs/cm² versus 184 hairs/cm² in the control group — a 7.5% increase versus a 1.6% decrease. That delta was sufficient for NMPA submission. What it took to get there: 14 months from formula lock to approved registration. Budget for the testing alone was approximately $45,000 USD. Most brands are not prepared for either number.

Honestly, the NMPA process is the most demanding of any market we work with for scalp claims. If China is a priority market, it needs to be in the brief from day one — not added after the formula is developed for other markets.

Instrumental Measurement and Study Design for Scalp Efficacy #

This section matters whether you are filing for regulatory purposes or building a brand claims package. The measurement method determines what you can say, and different methods have very different cost and complexity profiles.

Phototrichogram and TrichoScan are the gold standard for hair density and growth cycle assessment. Both require clipping a defined test area (typically 1.8 cm²), photographing at day 0 and day 3 (to distinguish growing from resting hairs), and using image analysis software to count and classify follicles. Reproducibility is good when the same technician and equipment are used throughout. The limitation is that it requires a shaved test area, which some subjects find unacceptable, and the analysis is time-intensive.

Trichoscopy (dermoscopy of the scalp) is faster and non-invasive, but more operator-dependent. We use it for interim assessments and for dandruff/seborrheic dermatitis studies where the primary endpoint is scale coverage or perifollicular redness rather than hair count.

Sebumeter and Tewameter measurements are relevant for scalp barrier and sebum studies. If your product claims to balance scalp sebum or improve scalp barrier function, these are the instruments you need. Sebumeter readings on the scalp typically run 150–300 µg/cm² in normal subjects; seborrheic scalp can run 400–600 µg/cm². A meaningful treatment effect in our experience is a 20–30% reduction from baseline.

For a 12-week brand claims study — not a regulatory submission, just a solid claims package — here is the design we recommend to brand partners:

Subjects: 40–50 subjects (we target 48 to allow for 15–20% dropout). Inclusion criteria should specify the condition you are targeting: mild-to-moderate dandruff, or self-reported hair thinning, or oily scalp. Do not mix conditions in one panel — the data becomes uninterpretable.

Measurements: Baseline, week 4, week 8, week 12. Primary instrumental endpoint (phototrichogram for hair density, trichoscopy for dandruff, sebumeter for sebum). Secondary endpoints: consumer self-assessment questionnaire (10–12 items, 5-point Likert scale), investigator global assessment, and standardized before/after photography.

Photography protocol matters more than most brands realize. Consistent lighting (we use a standardized light box at 5500K), consistent positioning (crown, vertex, and bilateral temporal views), consistent hair parting. One pilot batch of photography with 5 subjects before the study starts, to validate the protocol. We rejected the first photography vendor on one study because their lighting setup created shadows that made the scalp look worse at week 12 than at baseline — not because the product failed, but because the photography was inconsistent.

Consumer self-assessment questionnaires should be validated or at least pre-tested. We use a 12-item questionnaire covering scalp comfort, itch, flaking, hair feel, and overall satisfaction. Pre-test with 10 subjects before the study starts to check that the questions are understood as intended. This sounds obvious. It is consistently skipped.

The ICH Stability Guidelines are not directly applicable to efficacy studies, but the principle of defined timepoints and documented methodology applies. If you want the data to be usable for regulatory submission later, design the study to that standard from the start. Retrofitting a brand claims study into a regulatory dossier almost never works.

For brands developing scalp-targeted actives alongside broader hair care positioning, the study design needs to account for both scalp condition endpoints and hair quality endpoints — they require different measurement tools and sometimes different subject populations.

Where Most Brands Get the Claims Strategy Wrong #

The classification question and the claims question are not the same question, but they are deeply connected. We see two failure modes repeatedly.

The first is over-claiming on a cosmetic registration. A brand files as a cosmetic in the EU, then writes pack copy that implies treatment of a medical condition. “Clinically proven to stop hair loss” on a cosmetic product is not a cosmetic claim — it is a medicinal claim, and it triggers reclassification risk. The SCCS Scientific Opinion framework for borderline products is clear that intended purpose, as communicated to the consumer, determines classification. Your marketing copy is part of your regulatory submission, whether you think of it that way or not.

The second failure mode is under-claiming on a quasi-drug or special cosmetic registration. Brands go through the full registration process in Japan or China, then write conservative pack copy because their marketing team is not aware of what the registration actually permits. We have seen brands with a valid quasi-drug registration in Japan using claims language that would be acceptable for a general cosmetic. That is a significant waste of the regulatory investment.

The claims strategy needs to be developed in parallel with the regulatory strategy, not after it. When brand partners brief us on scalp products, the first question we ask is: which markets are you launching in, and what do you want to say on pack? Everything else — formula, actives, concentrations, study design — flows from that answer.

For brands building out a broader anti-aging scalp and hair positioning, the regulatory complexity compounds further, because age-related hair thinning claims sit at the intersection of cosmetic and quasi-drug territory in multiple markets simultaneously.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask on every scalp brief, and the answers determine everything that follows.

If you are targeting the US with anti-dandruff claims, we need to know upfront whether you want the OTC monograph route or a cosmetic-only positioning. The formula is different. The manufacturing pathway is different. The timeline is different by 3–4 months minimum.

If Japan is in scope, we need to know whether quasi-drug status is a commercial priority or a nice-to-have. Quasi-drug adds 6–9 months to the development timeline and requires a Japanese regulatory affairs partner on your side. If it is not a firm requirement, a well-formulated cosmetic with strong sensory performance often outperforms a quasi-drug product commercially — the quasi-drug positioning resonates with a specific Japanese consumer segment, but it is not universal.

For China, if you want hair loss prevention claims, budget 12–18 months and approximately $40,000–$60,000 USD for the full registration process including efficacy testing. If that is not feasible, we can formulate a general cosmetic scalp product with nourishing and comfort claims that does not require special registration — but you cannot use the 防脱发 claim.

One thing we are direct about with every brand: do not brief the formula first and the regulatory strategy second. We have rebuilt formulas from scratch because the hero active was not permitted at the desired concentration in the target market. That is expensive and demoralizing for everyone involved.

Frequently Asked Questions #

Q: We want to use minoxidil in our scalp serum for the EU market — is that possible as a cosmetic?

No. Minoxidil is classified as a medicinal substance in the EU and cannot be used in cosmetic products regardless of concentration. If you want a hair growth positioning in the EU, you need to work with cosmetic actives — adenosine, caffeine, peptide complexes — and frame claims around scalp nourishment and hair appearance rather than hair growth. We can build a strong formula in that space, but minoxidil is off the table.

Q: How long does the China NMPA special cosmetics registration actually take?

In our experience, 12–18 months from dossier submission to approval, assuming the efficacy data is clean and the submission is complete on first filing. Budget for at least one round of supplementary questions from NMPA — that adds 2–3 months in most cases. The efficacy testing itself takes 4–5 months before you can even submit. Start early.

Q: Can we use the same formula for Japan quasi-drug and EU cosmetic registration?

Sometimes, but not always. The quasi-drug positive list actives are generally permitted as cosmetic ingredients in the EU, so the formula itself may be compatible. The issue is concentration — quasi-drug concentrations are fixed by the Japanese positive list, and those concentrations may be higher than what you would choose for a cosmetic formula optimized for EU sensory performance. We usually end up with two variants: same base, different active concentration and sometimes different vehicle.

Q: What is the minimum study size for a credible brand claims package?

For a scalp efficacy study supporting marketing claims (not regulatory submission), we recommend a minimum of 40 subjects completing the study. That means enrolling 48–50 to account for dropout. Below 30 completers, the statistical power is too low to make meaningful claims, and sophisticated retail buyers will push back on the data. For regulatory submission in China, the NMPA-recognized testing institutions require a minimum of 60 subjects.

Q: We are launching in the US and South Korea simultaneously — do we need two separate studies?

Probably yes, or at minimum a study designed to generate data that satisfies both markets. US OTC monograph compliance does not require a clinical study — it requires formula and labeling compliance. But South Korea’s functional cosmetics pathway for hair loss claims requires human efficacy data from a recognized testing institution. A study designed to Korean MFDS standards can also support US marketing claims, but a US-only brand claims study may not meet Korean submission requirements. Design to the higher standard from the start.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.